0.21
price down icon1.87%   -0.004
after-market Handel nachbörslich: .23 0.02 +9.52%
loading
Schlusskurs vom Vortag:
$0.214
Offen:
$0.21
24-Stunden-Volumen:
1.70M
Relative Volume:
0.84
Marktkapitalisierung:
$8.35M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-51.06M
KGV:
-0.1522
EPS:
-1.38
Netto-Cashflow:
$-40.03M
1W Leistung:
+3.60%
1M Leistung:
+38.25%
6M Leistung:
-63.09%
1J Leistung:
-52.71%
1-Tages-Spanne:
Value
$0.21
$0.2574
1-Wochen-Bereich:
Value
$0.1826
$0.2574
52-Wochen-Spanne:
Value
$0.1315
$1.31

Viracta Therapeutics Inc Stock (VIRX) Company Profile

Name
Firmenname
Viracta Therapeutics Inc
Name
Telefon
858-400-8470
Name
Adresse
2533 S COAST HWY 101, CARDIFF
Name
Mitarbeiter
26
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
VIRX's Discussions on Twitter

Vergleichen Sie VIRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VIRX
Viracta Therapeutics Inc
0.21 8.35M 0 -51.06M -40.03M -1.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Viracta Therapeutics Inc Stock (VIRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-16 Herabstufung Leerink Partners Outperform → Market Perform
2022-02-01 Eingeleitet RBC Capital Mkts Outperform
2021-05-03 Eingeleitet H.C. Wainwright Buy
2021-04-26 Eingeleitet SVB Leerink Outperform
2021-03-25 Eingeleitet Evercore ISI Outperform

Viracta Therapeutics Inc Aktie (VIRX) Neueste Nachrichten

pulisher
Dec 17, 2024

Viracta Therapeutics' SWOT analysis: stock focus narrows amid pipeline shift - Investing.com

Dec 17, 2024
pulisher
Dec 15, 2024

Viracta Therapeutics, Inc. (NASDAQ:VIRX) Short Interest Update - Defense World

Dec 15, 2024
pulisher
Dec 13, 2024

Viracta Therapeutics Inc (NASDAQ: VIRX) Has Great Upside Potential - Stocks Register

Dec 13, 2024
pulisher
Dec 11, 2024

Viracta Therapeutics' SWOT analysis: focused strategy reshapes stock outlook By Investing.com - Investing.com Australia

Dec 11, 2024
pulisher
Dec 11, 2024

Epstein-Barr Virus (EBV) Market A Deep Dive into Current - openPR

Dec 11, 2024
pulisher
Dec 10, 2024

Viracta Therapeutics' SWOT analysis: focused strategy reshapes stock outlook - Investing.com

Dec 10, 2024
pulisher
Dec 01, 2024

Viracta Therapeutics faces Nasdaq delisting over non-compliance By Investing.com - Investing.com Australia

Dec 01, 2024
pulisher
Dec 01, 2024

Viracta Therapeutics faces Nasdaq delisting over non-compliance - Investing.com

Dec 01, 2024
pulisher
Nov 23, 2024

Viracta Therapeutics faces Nasdaq delisting risk - Investing.com India

Nov 23, 2024
pulisher
Nov 23, 2024

Viracta Therapeutics faces Nasdaq delisting risk By Investing.com - Investing.com Canada

Nov 23, 2024
pulisher
Nov 22, 2024

Contrasting ALX Oncology (NASDAQ:ALXO) & Viracta Therapeutics (NASDAQ:VIRX) - Defense World

Nov 22, 2024
pulisher
Nov 17, 2024

Royal Bank of Canada Cuts Viracta Therapeutics (NASDAQ:VIRX) Price Target to $2.00 - Defense World

Nov 17, 2024
pulisher
Nov 15, 2024

VIRX stock touches 52-week low at $0.15 amid market challenges - Investing.com UK

Nov 15, 2024
pulisher
Nov 14, 2024

Viracta Therapeutics Highlights Strategic Focus and Financials - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews

Nov 14, 2024
pulisher
Nov 13, 2024

Sunesis: Q3 Earnings Snapshot - mySA

Nov 13, 2024
pulisher
Nov 13, 2024

Viracta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024
pulisher
Nov 13, 2024

Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Nov 13, 2024
pulisher
Nov 13, 2024

Head and Neck Cancer Market Expected to Reach $9.07 Billion by 2030, Growing at 16.2% CAGR As Revealed In N... - WhaTech

Nov 13, 2024
pulisher
Nov 13, 2024

Viracta Cuts Workforce 42%, Narrows Focus on PTCL Drug as Cash Runway Tightens - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Natural Killer T-Cell Lymphoma Market 2024 Projections, - openPR

Nov 13, 2024
pulisher
Nov 08, 2024

Viracta Thera pins hopes on lead lymphoma program - The Pharma Letter

Nov 08, 2024
pulisher
Nov 07, 2024

VIRX stock touches 52-week low at $0.18 amid market challenges - Investing.com UK

Nov 07, 2024
pulisher
Nov 07, 2024

Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma - The Manila Times

Nov 07, 2024
pulisher
Nov 06, 2024

Viracta Therapeutics cuts workforce to focus on cancer program - Investing.com

Nov 06, 2024
pulisher
Nov 06, 2024

Viracta Therapeutics cuts workforce to focus on cancer program By Investing.com - Investing.com Canada

Nov 06, 2024
pulisher
Nov 06, 2024

Viracta Therapeutics Announces Reprioritization of - GlobeNewswire

Nov 06, 2024
pulisher
Nov 06, 2024

Viracta (VIRX) Cuts 42% of Workforce, Restructures Board Amid Strategic Shift | VIRX Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 04, 2024

Pharma takes aim at a wily foe — the Epstein-Barr virus - Yahoo Finance

Nov 04, 2024
pulisher
Oct 28, 2024

T-cell Lymphoma Market Segments Analysis Report 2024-2031 - InsightAce Analytic

Oct 28, 2024
pulisher
Oct 24, 2024

Advanced Gastric Carcinoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Oct 24, 2024
pulisher
Oct 22, 2024

Peripheral T-Cell Lymphoma Market Expected to Experience Major - openPR

Oct 22, 2024
pulisher
Oct 16, 2024

Head and Neck Cancer Market Share, Size, Growth and Forecast to 2031 - InsightAce Analytic

Oct 16, 2024
pulisher
Oct 10, 2024

Natural Killer T-Cell Lymphoma Market Trends and Growth - openPR

Oct 10, 2024
pulisher
Sep 30, 2024

Viracta Therapeutics' SWOT analysis: narrowed focus shapes stock outlook By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 30, 2024

Viracta Therapeutics' SWOT analysis: narrowed focus shapes stock outlook - Investing.com India

Sep 30, 2024
pulisher
Sep 19, 2024

Head and Neck Cancer Market to Reach $9.07 Billion by 2030, Growing at 16.2% CAGR - WhaTech

Sep 19, 2024
pulisher
Sep 11, 2024

Ionis Pharmaceuticals announces $500 million public offering | Biotechnology | The Pharmaletter - The Pharma Letter

Sep 11, 2024
pulisher
Sep 09, 2024

The Psychology of Viracta Therapeutics Inc Inc. (VIRX) Price Performance: Understanding Market Sentiment - The InvestChronicle

Sep 09, 2024
pulisher
Sep 04, 2024

Viracta Therapeutics Inc (VIRX) Stock: Navigating a Year of Volatility - The InvestChronicle

Sep 04, 2024
pulisher
Sep 03, 2024

Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire

Sep 03, 2024
pulisher
Sep 02, 2024

Are Smart Investors Making the Right Decision? Viracta Therapeutics Inc (VIRX) - SETE News

Sep 02, 2024
pulisher
Sep 02, 2024

Ratio Review: Analyzing Viracta Therapeutics Inc (VIRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Sep 02, 2024
pulisher
Sep 02, 2024

What is the investor’s view on Viracta Therapeutics Inc (VIRX)? - US Post News

Sep 02, 2024
pulisher
Aug 29, 2024

Viracta Therapeutics Inc (VIRX) can make a big difference with a little luck - SETE News

Aug 29, 2024
pulisher
Aug 28, 2024

Viracta Therapeutics Inc (VIRX)’s stock decline to 0.22 per share - US Post News

Aug 28, 2024
pulisher
Aug 27, 2024

Ratio Analysis: Unpacking Viracta Therapeutics Inc (VIRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Aug 27, 2024
pulisher
Aug 23, 2024

Viracta Therapeutics stock hits 52-week low at $0.27 - Investing.com

Aug 23, 2024

Finanzdaten der Viracta Therapeutics Inc-Aktie (VIRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Viracta Therapeutics Inc-Aktie (VIRX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Pomerantz Roger
Director
Nov 25 '24
Option Exercise
0.00
9,034
0
126,478
ROYSTON IVOR
Director
Aug 25 '24
Option Exercise
0.00
25,219
0
814,522
Pomerantz Roger
Director
Aug 25 '24
Option Exercise
0.00
9,034
0
117,444
Pomerantz Roger
Director
May 25 '24
Option Exercise
0.00
9,035
0
108,410
ROYSTON IVOR
Director
May 25 '24
Option Exercise
0.00
25,219
0
789,303
ROYSTON IVOR
Director
Feb 25 '24
Option Exercise
0.00
25,219
0
764,084
Pomerantz Roger
Director
Feb 25 '24
Option Exercise
0.00
9,034
0
99,375
Chevallard Daniel R.
CFO and COO
Feb 25 '24
Option Exercise
0.00
6,889
0
105,711
Chevallard Daniel R.
CFO and COO
Feb 27 '24
Sale
0.73
3,405
2,493
102,306
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
Kapitalisierung:     |  Volumen (24h):